CIRM Funded Clinical Trials

Phase 1 Safety Assessment of CPCB-RPE1, hESC-derived RPE Cell Coated Parylene Membrane Implants, in Patients with Advanced Dry Age Related Macular Degeneration

Mark Humayun
CIRM Grant:
DR3-07438 (Closed)
Award Value:
Trial Stage: 
Phase 1
Trial Status: 
Active, not recruiting
Targeted Enrollment:
16 ID:

Age-related macular degeneration is a progressive disease resulting in death of the retinal pigment epithelium (RPE) causing distortion to central vision and eventually to legal blindness. Regenerative Patch Technologies and scientists at the University of Southern California and UC Santa Barbara, are growing specialized cells of the retina (called retinal pigment epithelium) from embryonic stem cells, placing them on a single layer scaffold and implanting the combination device in the back of the eye to try to reverse blindness.


Open label, single arm study.


Safety. Efficacy - slow disease progression, maintain and restore visual acuity